Manages nasal symptoms of perennial nonallergic rhinitis. ANDA 77570, held by Hikma. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 77570 (Fluticasone Propionate), held by Hikma, was first approved by FDA on Jan 16, 2008, with 3 approved supplements and 0 published complete response letters.
Fluticasone propionate nasal spray, USP is indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged 4 years and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 16, 2008 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluticasone Propionate0.05MG/SPRAY · spray, metered;nasal | Fluticasone Propionate | Discontinued |
| Nov 14, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Dec 16, 2015 | Supplement 10Manufacturing | Approved | None posted |
| Jul 28, 2010 | Supplement 4Labeling | Approved | None posted |
| Jan 16, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters